liraglutide vs semaglutide vs tirzepatide vs. Weight Loss Drugs: Semaglutide, Tirzepatide,

Maintaining Results Data from similar medications shows that discontinuing treatment typically leads to significant weight regain within 6-12 months

Nat Rev Immunol 10:131144

Shiroky, J

Myostatin regulates pituitary development and hepatic IGF1

Retatrutide targets GLP-1, GIP, and glucagon receptors for comprehensive metabolic action Phase 2 trials showed up to 24% body weight loss over 48 weeks in participants The medication is administered as a once-weekly injection, similar to existing treatments Eli Lilly is developing Retatrutide, with Phase 3 trials currently underway UK availability is not expected until at least 2026-2027 following regulatory approval Weight Loss Treatment Comparison Calculator Estimate potential weight loss based on current clinical trial data for different medications Based on average clinical trial results

The lifetime risk of patients with NF-1 developing MPNSTs has been estimated at 813%, with a yearly risk of developing MPNSTs of 0.16% compared to 0.001% in the general population